POLICYBZR Q3 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,292 Cr
verified against source
Revenue YoY
48%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
PB Fintech delivered 48% revenue growth to INR 1,292 crore and 92% PAT growth to INR 92 crore in Q3 FY25. The outperformance was driven by health (+60%) and term insurance growth, partially offset by slower-than-expected savings business (30%+ but below 100% expectations). Total insurance premium reached INR 6,135 crore (+44% YoY). Trail revenue ARR grew 46% to INR 665 crore, providing visibility on future profitability. Health and life combined grew 47% YoY, indicating market share gains. New initiatives turned contribution margin positive at 3%, a key inflection point. Credit business remains challenged (-20% YoY) but secured lending (now 1.4x unsecured) provides diversification. The company reiterated its FY27 net income target of INR 1,000+ crore, supported by renewal premium of INR 2,042 crore. Management prioritizes growth over near-term profitability, accepting that fresh health business comes at near-zero margin. Key risks include: health growth compressing short-term margins, savings business cyclicality, and Paisabazaar drag of INR 40 crore. Management expects cost optimization from 1,500-2,000 vacant seats to reflect from Q4 onward.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated the November 2021 guidance based on renewals doubling every two years, stating current trajectory supports easy achievement.
- Board authorized negotiations 45 days ago; deep negotiations ongoing with identified investors for potential strategic partnership.
- 1,500-2,000 vacant office seats being vacated; notices given with depreciation and financing cost savings expected from Q4 FY25.
- Management explicitly declined to provide quarterly profit guidance, prioritizing growth over near-term profitability given 40%+ revenue growth rates.
Risks flagged
- Fresh health business comes at near-zero or slight loss margin, compressing overall contribution margins. This 'good stress' persists as long as new business growth outpaces renewals.
- Savings (unit-linked) grew slower than expected in Q3 due to market softness. January market performance has been weak, potentially impacting Q4. Management acknowledged market cycles affect performance.
- Credit business profitability is INR 40 crore worse than last year, partially offset by incremental EBITDA from other business segments. Management expects this to normalize.
- Analyst asked for specific health insurance market share data; management declined to share, making competitive positioning difficult to verify independently.
Key quotes
- Fresh business might have slightly higher yield than renewal business. Almost flat. It's almost flat, by the way.
- We are growth of premium-hungry. We are not growth of commission-hungry. I know that at some level, from a financial perspective, that sounds very stupid, but I think at another level, it's very smart.
- From the day of the IPO till today, our premium is about six times higher. But our commissions are exactly the same. Obviously, a six times larger player with larger market share should have been able to attract higher commissions if they wanted to muscle into it or something of that sort. That's not our intent.
Research modules